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BACKGROUND: Pancreas cancer is a dreaded disease with high mortality, despite progress in surgical and oncological treatments in
recent years. The field is hampered by a lack of good prognostic and predictive tumour biomarkers to be used during follow-up of
patients.
METHODS: The circulating level of type IV collagen was measured by ELISA in pancreas cancer patients and controls. The expression
pattern of type IV collagen in normal pancreas, pancreas cancer tissue and in pancreas cancer cell lines was studied by
immunofluorescence and Western blot techniques.
RESULTS: Patients with pancreas cancer have significantly increased circulating levels of type IV collagen. In pancreas cancer tissue high
levels of type IV collagen expression was found in close proximity to cancer cells in the tumour stroma. Furthermore, pancreas cancer
cells were found to produce and secrete type IV collagen in vitro, which in part can explain the high type IV collagen expression
observed in pancreas cancer tissue, and the increased circulating levels in pancreas cancer patients. Of clinical importance, our results
show that the circulating level of type IV collagen after surgery is strongly related to prognosis in patients treated for pancreas cancer
by pancreatico-duodenectomy with curative intent. Persisting high levels of circulating type IV collagen after surgery indicates a quick
relapse in disease and poor survival.
CONCLUSION: Our results most importantly show that stroma related substances can be evaluated as potential cancer biomarkers, and
thereby underline the importance of the tumour microenvironment also in this context.
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Pancreas cancer is still one of the most feared malignancies with a
poor prognosis. The overall median survival is 3–5 months, and
the 5-year survival rate is only 3% (Goldstein et al, 2004). This is
due to unspecific and diffuse symptoms, leading to late diagnosis
of the disease. Currently, the only known curative treatment is
surgical removal of a tumour at a local stage, and the procedure
most often used to treat cancerous tumours in the head of the
pancreas is pancreatico–duodenectomy (Whipple’s procedure). In
Whipple’s procedure the distal half of the stomach (optional), the
gall bladder, the distal portion of the common bile duct, the head
of the pancreas, duodenum, proximal jejunum and regional lymph
nodes are all removed. Although the results in surgical treatment
of pancreatic cancer have improved over the last decades, long-
term survival occurs in only 10–20% of patients (Goldstein et al,
2004). In fact, many patients diagnosed with a local operable
tumour turn out to suffer from spread disease. Taken together, this
indicates that there is a great need for new biomarkers to assist in
obtaining an early and accurate diagnosis, classify patients
correctly as having local (operable) or spread (non-operable)
disease. A good biomarker would also aid in evaluating treatment
effects, predicting prognosis and monitoring patients after
treatment for early detection of disease relapse.
Several different substances have been identified as potential
biomarkers in pancreas cancer, such as LMO4 (Murphy et al,
2008), c-kit (Kimura et al, 2007), TPS, CA 19-9, VEGF-A and CEA
(Slesak et al, 2004; Sandblom et al, 2008) in serum, and telomerase
activity in pancreatic juice (Uehara et al, 2008). However, few of
these are used in clinical praxis, and the specificity and sensitivity
for many have been questioned.
A characteristic feature of pancreas cancer is the dens fibrous
stroma surrounding the cancer cells and referred to as tumour
desmoplasia. It has been suggested that desmoplasia is of
importance for cancer cell growth and survival, which is supported
by the fact that the less aggressive mucinous type of pancreatic
carcinoma is not surrounded by such an abundant desmoplastic
stroma (Kimura et al, 1998). This indicates that the extracellular
matrix (ECM) is of particular interest in pancreas cancer.
Type IV collagen is an ECM protein found in all basement
membranes (BM) (Khoshnoodi et al, 2008). Type IV collagen
forms a supramolecular network in the basement membrane that
influences cell adhesion, migration and differentiation of epithelial
cells (Khoshnoodi et al, 2008). This BM protein can be made from
six different a-chains, a1(IV)–a6(IV), which appear in different
combinations to form triple helical molecules called protomers
(Hudson et al, 2003) that further organise into a sheet-like
structure in the BM. Tissues show unique expression patterns of
a(IV)-chains, which renders different functional and structural
properties to the BMs in that tissue.
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collagen can act as endogenous antiangiogenic agents. Arresten,
canstatin and tumstatin (fragments derived from a1(IV)-, a2(IV)-
and a3(IV)-chains, respectively) have been shown to inhibit
angiogenesis and tumour growth in vivo (Kamphaus et al, 2000;
Kalluri, 2003; Sund et al, 2005). In addition, fragments derived
from a4(IV)-, a5(IV)- and a6(IV)-chains were found to have
antiangiogenic features in vitro (Karagiannis and Popel, 2007).
Although the role of type IV collagen in angiogenesis and cancer
progression has been extensively studied, few have evaluated this
protein as a potential biomarker. However, a correlation between
levels of type IV collagen in peritoneal fluid and survival time in
patients with peritoneal disseminated gastric and colorectal cancer
has been shown (Korenaga et al, 1998).
We show here the expression pattern of different a(IV)-chains in
normal pancreas and pancreatic cancer tissue, as well as analyse
the expression of type IV collagen by pancreas cancer cells in vitro.
We also measure the circulating levels of type IV collagen in
patients with pancreas cancer before and after treatment, and
introduce type IV collagen as a promising future biomarker for
identification of patients at high risk of quick relapse and poor
prognosis after surgery.
MATERIALS AND METHODS
Patients and samples
Patients with pancreas cancer were admitted to the Department of
Surgery, Umea ˚ University Hospital and evaluated by CT scan, MRI
and laparoscopy. Patients who were considered operable under-
went a curatively aimed pancreatico–duodenectomy (Whipple’s
procedure). One patient was operated with an expanded Whipple’s
procedure (total pancreatectomy), and one obtained intraoperative
radiotherapy (IORT). Plasma samples were collected from these
patients before (Pre Op; n¼9) and after surgery (Post Op, n¼9).
In the survival analysis additional patients were added (n¼5),
where only samples after surgery were available. Postoperative
plasma samples were collected 4 weeks or more after surgery.
Control samples were collected from patients (n¼8) admitted to
the hospital for a non-malignant disease. Patient characteristics are
shown in Table 1. The samples were frozen and stored at  801C
until analysis. Pancreas tissue samples from patients with pancreas
cancer (n¼6) and controls (n¼5) were snap frozen in liquid
nitrogen and stored at  801C until analysis. Informed consent was
obtained from all patients. The ethical committee at the Medical
faculty of Umea ˚ University approved the study.
Cell culture
Two well characterised human pancreatic adenocarcinoma cell
lines were used, HPAC and CFPAC-1. Both cells lines were kindly
provided by Professor Helena Edlund, Umea ˚ University. HPAC
(ATCC, CRL-2119) is a human pancreatic adenocarcinoma cell line
of ductal origin from a woman with moderate to well differentiated
pancreatic adenocarcinoma (Gower, 1994). CFPAC-1 (ATCC, CRL-
1918) is derived from a ductal adenocarcinoma from a male patient
with cystic fibrosis (Schoumacher et al, 1990). HPAC were cultured
with 1:1 mixture of Dulbecco’s modified Eagle’s and Ham’s F12
medium (DMEM/F12), CFPAC-1 with 90% Iscove’s modified
Dulbecco’s medium (IMDM), both supplemented with 10% fetal
bovine serum, penicillin (10
5IUl
 1) and streptomycin (100mgl
 1)
and grown in an incubator at 371C in an atmosphere of 5% CO2.
Tissue and cell staining
Hematoxylin and eosin (H&E) and Masson’s trichrome staining
(MTS) were performed according to standard protocols. Immu-
nohistochemical staining was performed on frozen sections (six
micrometer) and immunocytochemical staining on HPAC and
CFPAC-1 cells cultured on Falcon Culture Slides (BD Biosciences,
Erembodegem, Belgium) using methods described earlier (Hama-
no et al, 2003) with the following primary antibodies and dilu-
tions; mouse-anti-a1(IV)NC1 (Wieslab, Malmo, Sweden, MAB1,
1:75) (Johansson et al, 1991), mouse-anti-a2(IV)7S (Chemicon,
Billerica, MA, USA, MAB1910, 1:400), mouse-anti-a3(IV)NC1
(Wieslab MAB3, 1:75) (Johansson et al, 1991), mouse-anti-
a5(IV)NC1 (Wieslab MAB5, 1:75) (Ding et al, 1994), rabbit-anti-
collagen type IV (polyclonal, MP Biomedicals LLC, Illkirch,
France) and sheep-anti-CD31 (R&D systems, Abingdon, UK).
Unfortunately, no specific antibodies against the a4(IV)- and
a6(IV)-chains are commercially available. For detection of
a5(IV)NC1, tissue was denatured with 6M urea–0.1M glycine
before staining. Secondary antibodies used were; donkey-anti-
sheep FITC (Jackson ImmunoResearch lab Inc., Newmarket, UK,
1:100), and donkey-anti-mouse TRITC (Jackson ImmunoResearch
lab Inc., 1:100) and donkey-anti-rabbit FITC (Jackson ImmunoR-
esearch lab Inc., 1:100). Sections were mounted with medium
containing DAPI (Vectashield, Vector Laboratories Inc.). Positive
control staining for each antibody was performed on tissue known
to express the antigen in question. As negative controls, primary
antibodies were omitted and sections were incubated with
secondary antibodies only.
Western blot
HPAC and CFPAC cells were cultured to subconfluency, then
serum-starved for 1–2 days. Cells were lysed as described earlier
(Aebi et al, 1996). The proteins secreted to the cell media were
collected by ethanol precipitation and dissolved in reducing buffer.
In all, 20mg of protein from the cell layer and 25mg of protein from
the cell media were loaded onto a 12% SDS–polyacrylamide gel.
As a positive control 500ng of recombinant human arresten (for
a1(IV)NC1) (Colorado et al, 2000) and 100ng canstatin (for
a2(IV)NC1) (Kamphaus et al, 2000) were used. Recombinant
protein was kindly provided by Professor Raghu Kalluri, HMS,
Boston. A rabbit-anti-type IV collagen (1:500) (Kamphaus et al,
2000) antibody, detecting both a1(IV)- and a2(IV)-chains, was
used as a primary antibody, and peroxidase-conjugated goat-anti-
rabbit-IgG (Sigma, Stockholm, Sweden, A 9169, 1:12000) as
Table 1 Patient characteristics
Control
Patients with pre- and
postoperative samples
Patients with postoperative
samples only
Number 8 9
a 5
a
Sex (percentage of females/males) 62/38 56/44 60/40
Primary diagnosis (%) Gallstone disease (75%) Pancreas adenocarcinoma (78%) Pancreas adenocarcinoma (100%)
Diverticular disease (25%) Papillary carcinoma (22%)
Average age (years) (range) 51 (27–71) 64 (53–76) 71 (65–77)
P-value vs contol — 0.06 —
aPostoperative samples from these groups together are included in the survival analysis (n¼14).
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Figure 1 Expression of type IV collagen in normal pancreas. (A, B) In normal pancreas tissue a1(IV)- and a2(IV)-chains are expressed in epithelial and
vascular BMs (in red). Blood vessels are visualised by the endothelial cell marker CD31 (in green) and nuclei by DAPI (in blue). (C, D) Light microscopy
images stained with H&E (C) and MTS (D) of the corresponding areas in normal pancreas. In (D) MTS collagen fibres are stained blue. Magnification  40 in
all panels.
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Figure 2 Expression of type IV collagen in pancreas cancer. (A, B) In pancreas cancer tissue a1(IV)- and a2(IV)-chains are strongly expressed (in red) in
the tumour stroma (marked T) and in the VBM, whereas the expression is low in the surrounding desmoplastic area that contains an abundance of fibrillar
collagens (marked D). Blood vessels are visualised by the endothelial cell marker CD31 (in green) and cell nuclei by DAPI (in blue). Insets show a close-up of
the tumour stroma. (C, D) Light microscopy images stained with H&E (C) and MTS (D) of the corresponding areas in pancreas cancer. In (D) MTS the
collagen fibres are stained blue. Magnification  20 in all panels and  40 in inserts.
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(ECL) (GE Healthcare, Uppsala, Sweden).
ELISA assay
Circulating levels of type IV collagen in patients and controls were
measured by using Serum Collagen IV EIA (Argutus Medical,
Dublin, Ireland). Samples were run in duplicates and according to
the manufacturer’s protocol. In these ELISA-assays two monoclonal
antibodies (clones 4H12 and 1D3) directed against the collagenous
domain of type IV collagen are used (Obata et al, 1989).
Statistics
Statistical analysis when comparing different groups were per-
formed by using the Student’s t-test. The variance of groups was
tested for equality by an F-test prior to a t-test analysis. A two-
tailed analysis was used throughout. Values in text and figures are
presented as mean±s.d. SPSS version 16.0 was used for regression
and survival analysis.
RESULTS
High expression of type IV collagen is observed in the
tumour stroma
We analysed the expression pattern of the different a-chains of type
IV collagen in normal pancreas and in pancreas cancer tissue. In
normal pancreas a1(IV)- and a2(IV)-chains are highly expressed in
vascular basement membranes (VBM) and epithelial basement
membranes (Figure 1), whereas the a3(IV)- and a5(IV)-chains could
not be detected (data not shown). In pancreas cancer the tissue
morphology is changed, with no organised ductal structures, and
strong a1(IV)- and a2(IV)-chain expression is now observed close to
the cancer cells in the tumour stroma and the VBMs (Figure 2).
Interestingly, in the desmoplastic reaction surrounding the tumour,
only low levels of type IV collagen expression could be observed.
The a3(IV)- and a5(IV)-chains of type IV collagen were not
expressed in pancreas cancer (data not shown).
Type IV collagen is produced by pancreas cancer cells
in vitro
To further study whether the observed type IV collagen is solely
expressed by the stromal cells, such as the stellate cells surrounding
the cancer cells in the tumour, or partly by the cancer cells
themselves, we performed in vitro studies on two well characterised
pancreas cancer cell lines HPAC and CFPAC-1. Western blot analysis
of cell lysate and media, and immunocytochemical staining, show
that both a1(IV) and a2(IV), the two a-chains that were strongly
expressed in the tumour stroma in pancreas cancer tissue, are
produced by the cancer cells and secreted to the media in both cell
lines (Figure 3). These results suggest that the type IV collagen
observed in the tumour stroma in vivo could be, at least in part,
produced by the pancreas cells themselves.
Changes in circulating levels of type IV collagen in patients
with pancreas cancer
Circulating levels of type IV collagen fragments were measured
with ELISA in control patients and pancreas cancer patients before
and after surgery (Figure 4A). A significant increase of circulating
type IV collagen could be observed preoperatively when compared
with controls 106±32 vs 154±40ngml
 1. After surgery the type
IV collagen levels remained high (222±127ngml
 1) when
compared with the controls, and no statistically significant change
was observed when comparing with the levels before surgery.
However, the variation within the postoperative group was high,
which prompted us to plot the levels before and after surgery for
individual patients (Figure 4B). It turned out that for five patients
the levels increased after surgery and for four the levels decreased.
Postoperative levels of type IV collagen correlates to
survival
This observation made it interesting to look further into whether
the observed differences in circulating type IV collagen levels after
surgery are reflected in differences in prognosis and survival. We
therefore plotted postoperative type IV collagen levels against
registered survival after surgery (Figure 4C). At this point, five
patients for whom only samples after surgery are available were
added to the postoperative group (Table 1). We observed a
significant correlation, where high circulating levels of type IV
collagen after surgery corresponded to poor prognosis and short
survival time. The difference in survival between patients with high
postoperative levels of type IV collagen (4200ngml
 1), and those
with lower levels (o200ngml
 1) can also be illustrated in a
survival curve (Figure 4D). Median survival time in the group with
persistent high levels of circulating type IV collagen is 6.1 months
after surgery, compared with 28.9 months in the group with low
levels. No correlation between total bilirubin levels, C-reactive
protein levels and type IV collagen levels were observed (data not
shown). Preoperative levels of circulating type IV collagen were
also tested for correlation to survival, but no significant correlation
could be observed in this case (data not shown).
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Figure 3 Expression of type IV collagen in pancreas cancer cell lines. (A)
Cell lysates of HPAC and CFPAC-1 contain type IV collagen-derived
fragments, demonstrating production of this collagen by cells. The complete
a(IV)-chain is too large to enter the gel, and the bands visualised
correspond to fragments of different sizes cleaved off from the a-chain in a
constantly ongoing turnover process involving different tumour-associated
proteases. In the cell media type IV collagen-derived fragments could also
be observed in both cell lines, indicating secretion of type IV collagen from
the cells to the media. As positive controls recombinant human arresten
(a1(IV)NC1) and canstatin (a2(IV)NC1) were used. As negative control
HPAC cell lysate and cell media were incubated without primary antibody.
(B–D) Immunocytochemical analysis of HPAC and CFPAC-1 cells confirm
that type IV collagen is produced by pancreas cancer cell lines. In (B) type
IV collagen is visualised using a polyclonal antibody, in (C) an antibody
specific for the a1(IV)-chain is used and in (D) an antibody specific for the
a2(IV)-chain. Type IV collagen is shown in red and cell nuclei in blue
(DAPI). Magnification  40 in B–D.
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It has previously been shown that in the BM of the pancreatic ducts
a1(IV)-, a2(IV)-, a5(IV)- and a6(IV)-chains are expressed in
normal pancreas, whereas the a5(IV)- and a6(IV)-chains are lost
from the BM in the pancreatic duct in cancer (Kadono et al, 2004).
In this study, we analysed the expression pattern of type IV
collagen in the exocrine part and distal pancreatic ducts of the
normal pancreas and in pancreas cancer. In the normal pancreas
we could observe both a1(IV)- and a2(IV)-chain staining in the
BM surrounding the acini structures and distal ducts in the
exocrine pancreas. This suggests the presence of the a1a2a2
protomer of type IV collagen in this part of the normal pancreatic
tissue, as we could not see any expression of the a3(IV)- and
a5(IV)-chains.
In pancreas cancer, high levels of a1(IV)- and a2(IV)-chains
were expressed in the direct proximity to the cancer cells in the
tumour stroma. No expression of the a3(IV)- and a5(IV)-chains
were observed. This is well in line with earlier studies of the
expression pattern of type IV collagen in pancreatic adenocarci-
nomas (Lee et al, 1994; Linder et al, 2001). The typical strong
desmoplastic reaction that surrounds the tumour cells in pancreas
cancer is composed of connective tissue, predominantly type I
collagen (Goldstein et al, 2004). Most interestingly, only low levels
of a1(IV)- and a2(IV)-chain expression was found in the areas of
tumour desmoplasia, indicating that type IV collagen has a distinct
expression pattern when compared with the fibrillar collagens
found in this area.
As an adenocarcinoma develops and becomes invasive it has to
penetrate the BM. In this process matrix metalloproteinases
(MMPs) are involved in remodelling the basement membrane
(Stallings-Mann and Radisky, 2007). We have previously shown an
upregulated expression of MMP-3 and MMP-9 in pancreas cancer
tissue (Ohlund et al, 2008), and interestingly both these proteases
have type IV collagen as a substrate (Nyberg, 2005). The altered
expression pattern of type IV collagen observed in pancreas cancer
tissue can therefore partly be due to disruption and reorganisation
of pre-existing BMs in the tumour area by MMPs, but this would
not wholly explain the expression pattern observed. The expres-
sion pattern of type XVIII collagen/endostatin, another component
of the BM, is also altered in pancreas cancer (Ohlund et al, 2008).
However, the expression pattern of type XVIII collagen does not
resemble the expression pattern for type IV collagen in pancreas
cancer. For type XVIII collagen the expression in tumour stroma is
lower than that for type IV collagen, which indicates that various
components of the ECM could have specific roles in the regulation
of the tumour microenvironment of a cancer. Our findings also led
us to the conclusion that a part of the observed type IV collagen
must be produced by either stromal cells and/or cancer cells. In
our subsequent in vitro experiments on two pancreas cancer cell
lines, we could verify that pancreas adenocarcinoma cells produce
and secrete type IV collagen. Our results therefore indicate that the
expression pattern of type IV collagen observed in pancreas cancer
tissue is a result of remodelling of pre-existing type IV collagen,
together with de novo production by the cancer cells. It has been
shown in vitro in other human cancer cells, such as glioblastoma
and melanoma cell lines, that type IV collagen is produced by the
cancer cell (Bouterfa et al, 1999). Most interestingly, it has been
reported that type IV collagen production exceeds that of other
well known ECM proteins, in several different pancreas cancer cell
lines (Lohr et al, 1994). This further underlines the possible
importance of type IV collagen in progression of pancreas cancer.
This is the first description of increased circulating type IV
collagen levels in patients with pancreas cancer. We believe that
this increase is due to the breakdown of existing BMs by the
tumour, combined with type IV collagen production and secretion
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Figure 4 Change in circulating levels of type IV collagen in patients with pancreas cancer and correlation to survival. (A) In pancreas cancer patients
circulating type IV collagen levels are increased compared with controls with non-malignant disease (P¼0.014). After surgery the circulating levels remain
high (P¼0.03 vs controls), but error bars indicate great variance within the postoperative group. Values are presented as mean±s.d. (B) Pre- and
postoperative levels of circulating type IV collagen in individual patients. Five patients show increased levels after surgery, four decreased. Asterisk (*)
indicates papillary carcinomas. (C) Postoperative levels of type IV collagen correlate to survival (Po0.001, r
2¼0,809, n¼14). High postoperative levels
correlate to short survival. Closed circle (K) indicates patients that are alive (papillary carcinomas). (D) Kaplan–Meier survival curve. Patients with high
levels of circulating type IV collagen after surgery (cutoff¼200ngml
 1) show significantly shorter survival than patients with low levels, Po0.001 (log-rank
test). The cross (þ) indicates patients still alive (papillary carcinomas).
Type IV collagen in pancreas cancer
DO ¨ hlund et al
95
British Journal of Cancer (2009) 101(1), 91–97 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
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collagen levels have prognostic value when predicting prognosis
after surgery with curative intent. On the other hand, preoperative
circulating type IV collagen levels do not predict prognosis. This is
most likely due to the fact that preoperative level of circulating
type IV collagen corresponds to the total tumour load. One can
speculate that a large primary tumour can produce high levels of
type IV collagen, because of both matrix remodeling and
expression by the cancer cells, but it can nevertheless be a locally
growing tumour with good prognosis. After successful removal of
the primary tumour, the type IV collagen levels instead reflect the
metastatic tumour load, and high levels in the postoperative
situation therefore could correspond to spread disease and poor
prognosis. Our findings indicate that by measuring circulating
levels of type IV collagen soon after surgery, patients at high risk of
quick relapse and poor prognosis can be identified in an early
stage and be offered more aggressive adjuvant therapy.
Attachment to the BM is crucial for the survival and growth of
epithelial cells. Integrin receptors play a role in anchoring the cells
to the ECM and in providing survival signalling. If the epithelial
cell looses contact with the BM, a cascade of events is initiated
eventually leading to apoptosis (Hynes, 2002; Huveneers et al,
2007). In the transformation process from a local and benign, to an
invasive and malignant cancer cell, this mechanism must be
overrun, otherwise apoptosis will be induced as soon as the BM is
broken down to make tumour growth possible. It was shown
earlier that the integrin–ECM axis plays an important role in
regulating growth and migration of pancreas cancer cells, and that
many integrin receptors are upregulated in pancreas cancer
(Grzesiak et al, 2007). Recent evidence also points at a1b1 integrin
functioning as a type IV collagen receptor in pancreas cancer cells
(Grzesiak and Bouvet, 2007). In this study, we show that high levels
of type IV collagen is present in the close proximity to the cancer
cells, and that cancer cells produce and secrete type IV collagen.
We hypothesize that pancreas cancer cells produce BM proteins,
such as type IV collagen, which then are secreted to the tumour
surroundings and form basement membrane-like structures that
the cancer cells can anchor to and by this stimulate cell growth, cell
migration and perhaps avoid apoptosis.
Most importantly our study shows that a tumour stroma-
derived substance could be a promising future tumour biomarker
in evaluating prognosis and predict the effect of cancer treatment.
This underlines the importance of expanding the horizon beyond
the cancer cell, when searching for novel tumour biomarkers.
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